Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer

Abstract Therapies targeting somatic bystander genetic events represent a new avenue for cancer treatment. We recently identified a subset of colorectal cancer (CRC) patients who are heterozygous for a wild-type and a low activity allele (NAT2*6) but lack the wild-type allele in their tumors due to...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Veronica Rendo, Snehangshu Kundu, Natallia Rameika, Viktor Ljungström, Richard Svensson, Kimmo Palin, Lauri Aaltonen, Ivaylo Stoimenov, Tobias Sjöblom
Format: article
Langue:EN
Publié: Nature Portfolio 2020
Sujets:
R
Q
Accès en ligne:https://doaj.org/article/0075eeada5c6431e9aaae378bc12e7b8
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires